Kevin Harrington, Professor in Biological Cancer Therapies at Institute of Cancer Research, shared Emrullah Yilmaz’s post on LinkedIn, adding:
“Fantastic news.
Very excited to see this recognition of the really promising data that has accrued around the use of amivantamab in relapsed and/or metastatic H and N cancer. Really looking forward to the phase III evaluations that hopefully will signal real benefit for patients.”
Quoting Emrullah Yilmaz, Senior Medical Director at Johnson and Johnson Innovative Medicine, on LinkedIn:
“It is exciting to share that amivantamab has received US FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
based on the data from our ongoing OrigAMI-4 study.
There is a significant unmet need for the treatment of head and neck cancers. Having witnessed the challenges these cancers present and the burden on patients during my years as a head and neck oncologist, I am pleased to work with an exceptional team within JNJ on the development of amivantamab for these cancers with poor outcomes.”
Other articles featuring Kevin Harrington and Emrullah Yilmaz on OncoDaily.